GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2013

Pfenex Awarded Contract from Leidos to Continue Development of Malaria Antigen

  • Pfenex has received a subcontract from Leidos to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). The contract follows successful preclinical studies performed by Leidos collaborators to evaluate the Rh5 antigen, which was produced using the Pfenex Expression TechnologyTM platform.

    Funding comes from Leidos’ prime Malaria Vaccine Production and Support Services contract from the National Institute of Allergy and Infectious Diseases (NIAID). Pfenex will immediately commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies.

    This is the second contract awarded to Pfenex for the development of critical, hard-to-express malaria antigens. In 2011, Pfenex received a $3.1 million award from Leidos to develop a new malaria vaccine.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?